Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
A phase 3 trial of Pembrolizumab, Atezolizumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by InSightec, now recruiting.
Overview
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets is a phase 3 interventional study registered as NCT05317858 by InSightec, with 30 participants planned, started 2022-08-12 and due to reach its primary completion in 2027-06-01. Interventions recorded: Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab. Conditions listed: Brain Tumor, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati
Shares Atezolizumab, Nivolumab, Pembrolizumab, Small-cell lung cancer.
- TrialEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL
Shares Cemiplimab, Atezolizumab, Nivolumab, Small-cell lung cancer.
- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Shares Atezolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Nivolumab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.